Drug Trial Radar · NCT02555683
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
894
Actual
Start
Dec 11, 2015
Primary completion
Oct 21, 2019
Study completion Nov 4, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations: * patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population) * patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).
Conditions
- Asthma
Interventions
QAW039Drug
QAW039 150 mg once daily
QAW039Drug
QAW039 450 mg once daily
PlaceboDrug
Placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils SubpopulationTime frame: Baseline, Week 52
- Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall PopulationTime frame: Baseline, Week 52
Locations
234 sites in 27 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Litchfield Park, Arizona
Novartis Investigative Site
Peoria, Arizona
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Hawaiian Gardens, California
Novartis Investigative Site
Newport Beach, California
Novartis Investigative Site
Redondo Beach, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
Torrance, California
Novartis Investigative Site
Westminster, California
Novartis Investigative Site
New Haven, Connecticut
Novartis Investigative Site
Brandon, Florida
Novartis Investigative Site
New Smyrna Beach, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Ormond Beach, Florida
Novartis Investigative Site
Sebring, Florida
Novartis Investigative Site
Winter Park, Florida
Novartis Investigative Site
Gainesville, Georgia
Novartis Investigative Site
Marietta, Georgia
Novartis Investigative Site
Crowley, Louisiana
Novartis Investigative Site
Zachary, Louisiana
Novartis Investigative Site
Bangor, Maine
Novartis Investigative Site
Gaithersburg, Maryland
Novartis Investigative Site
White Marsh, Maryland
Novartis Investigative Site
Livonia, Michigan
Novartis Investigative Site
Ypsilanti, Michigan
Novartis Investigative Site
Picayune, Mississippi
Novartis Investigative Site
Bellevue, Nebraska
Novartis Investigative Site
Lincoln, Nebraska
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Corning, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Gastonia, North Carolina
Novartis Investigative Site
Monroe, North Carolina
Novartis Investigative Site
New Bern, North Carolina
Novartis Investigative Site
Whiteville, North Carolina
Showing 40 of 234 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.